Tarsus Pharmaceuticals Quarterly Income Statement
NASDAQ: TARSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Tarsus Pharmaceuticals revenue and earnings
In the quarter ended Jun 30, 2026, Tarsus Pharmaceuticals generated $173.9 million in revenue, up 69.4% from the same quarter a year earlier. Tarsus Pharmaceuticals reported a net loss of $18.6 million, compared with a loss of $20.3 million a year earlier. Gross margin was 93.0% (down from 93.9%) and operating margin -11.4%.
Diluted earnings per share came in at -$0.43.
Summary generated from market data by MetaCap's automated system. Methodology
Tarsus Pharmaceuticals income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 173.91M | 162.05M | 151.67M | 118.70M | 102.66M | 78.33M | 66.41M | 48.12M | 40.81M | 27.61M | 13.08M | 1.87M |
| Revenue growth (YoY) | +69.41% | +106.87% | +128.39% | +146.68% | +151.54% | +183.68% | +407.86% | +2471.78% | — | +1004.56% | +30.76% | — |
| Cost of Revenue | 12.11M | 9.40M | — | — | 6.24M | 5.21M | — | — | — | — | — | — |
| Gross Profit | 161.80M | 152.66M | — | — | 96.42M | 73.12M | — | — | — | — | — | — |
| Operating Expenses | 181.71M | 158.78M | — | — | 118.61M | 99.40M | — | — | — | — | — | — |
| Research & Development | 31.01M | 22.35M | 18.04M | 16.28M | 15.59M | 14.41M | 16.87M | 12.13M | 12.32M | 12.07M | 13.30M | 12.11M |
| Selling, General & Admin | 150.70M | 136.43M | 130.68M | 108.63M | 103.01M | 85.00M | 69.03M | 57.91M | 58.79M | 51.58M | — | — |
| Operating Income | -19.91M | -6.12M | -7.98M | -14.53M | -22.18M | -26.28M | -24.42M | -25.16M | -33.30M | -37.68M | -44.45M | -40.94M |
| Interest Expense | 2.16M | 2.13M | 2.21M | 2.27M | 2.24M | 2.21M | 2.31M | 2.44M | 2.11M | 983.00K | 989.00K | 858.00K |
| Other Income (Expense) | 4.07M | 1.51M | 1.66M | 1.94M | 1.84M | 1.16M | 1.31M | 1.74M | 12.00K | 1.95M | 2.55M | 1.79M |
| Income Tax | 2.72M | 2.35M | — | — | 0 | 0 | — | — | — | — | 0 | 0 |
| Net Income | -18.55M | -6.97M | -8.37M | -12.59M | -20.34M | -25.12M | -23.11M | -23.42M | -33.29M | -35.73M | -41.90M | -39.15M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.43 | -0.16 | -0.17 | -0.30 | -0.48 | -0.64 | -0.57 | -0.61 | -0.88 | -1.01 | -1.29 | -1.28 |
| EPS (Diluted) | -0.43 | -0.16 | -0.17 | -0.30 | -0.48 | -0.64 | -0.57 | -0.61 | -0.88 | -1.01 | -1.29 | -1.28 |
| Shares Outstanding (Basic) | 43.39M | 42.96M | — | 42.61M | 42.36M | 39.35M | — | 38.38M | 37.82M | 35.30M | — | 30.62M |
| Shares Outstanding (Diluted) | 43.39M | 42.96M | — | 42.61M | 42.36M | 39.35M | — | 38.38M | 37.82M | 35.30M | — | 30.62M |
| EBITDA | -19.11M | -5.92M | -7.77M | -14.33M | -21.98M | -26.06M | -24.23M | -24.96M | -33.20M | -37.51M | -44.20M | -40.73M |
| Gross Margin | 93.03% | 94.20% | — | — | 93.92% | 93.35% | — | — | — | — | — | — |
| Operating Margin | -11.45% | -3.78% | -5.26% | -12.24% | -21.61% | -33.55% | -36.77% | -52.29% | -81.60% | -136.47% | -339.94% | -2187.87% |
| Net Margin | -10.67% | -4.30% | -5.52% | -10.60% | -19.81% | -32.07% | -34.80% | -48.67% | -81.57% | -129.39% | -320.45% | -2092.36% |
This table shows 12 quarterly periods of Tarsus Pharmaceuticals's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow TARS's reporting calendar. What is a income statement?